Treatment with neutralizing CCL2 Ab suppressed chronic liver inflammation, reduced liver damage and both liver carcinoma incidence and tumor burden by downregulating pro-inflammatory pSTAT3, c-MYC, and NF-κB signals. This evidence concerns the gene CCL2 and neoplasm.